Literature DB >> 9802273

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

F Forette1, M L Seux, J A Staessen, L Thijs, W H Birkenhäger, M R Babarskiene, S Babeanu, A Bossini, B Gil-Extremera, X Girerd, T Laks, E Lilov, V Moisseyev, J Tuomilehto, H Vanhanen, J Webster, Y Yodfat, R Fagard.   

Abstract

BACKGROUND: Systolic hypertension increases the risk of dementia in elderly people. The vascular dementia project, set up in the framework of the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, investigated whether antihypertensive drug treatment could reduce the incidence of dementia.
METHODS: Eligible patients had no dementia, were at least 60 years old, and had a blood pressure when seated of 160-219 mm Hg systolic and below 95 mm Hg diastolic. Active treatment consisted of nitrendipine (10-40 mg/day) with the possible addition of enalapril (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs, titrated or combined to reduce the systolic blood pressure by at least 20 mm Hg to reach a value below 150 mm Hg. Cognitive function was assessed by the mini mental state examination (MMSE). If the MMSE score was 23 or less, diagnostic tests for dementia were done (DSM-III-R criteria). The cause of dementia was established by the modified ischaemic score with brain imaging or the Hachinski score.
FINDINGS: Median follow-up by intention to treat was 2.0 years. Compared with placebo (n=1180), active treatment (n=1238) reduced the incidence of dementia by 50% from 7.7 to 3.8 cases per 1000 patient-years (21 vs 11 patients, p=0.05). The median MMSE score at randomisation was 29 in both treatment groups. At the last available assessment, systolic and diastolic blood pressure were, respectively, 8.3 mm Hg and 3.8 mm Hg lower (p<0.001) in the active-treatment group, but on average the MMSE scores did not change in either group. In the control patients, however, the MMSE decreased (p=0.04) with decreasing diastolic blood pressure, whereas in the active-treatment group MMSE scores improved slightly (p=0.01) with greater reduction in diastolic blood pressure (p=0.002 for between-group difference).
INTERPRETATION: In elderly people with isolated systolic hypertension, antihypertensive treatment was associated with a lower incidence of dementia. If 1000 hypertensive patients were treated with antihypertensive drugs for 5 years 19 cases of dementia might be prevented.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802273     DOI: 10.1016/s0140-6736(98)03086-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  258 in total

Review 1.  Canadian Consensus Conference on Dementia: a physician's guide to using the recommendations.

Authors:  C J Patterson; S Gauthier; H Bergman; C A Cohen; J W Feightner; H Feldman; D B Hogan
Journal:  CMAJ       Date:  1999-06-15       Impact factor: 8.262

Review 2.  Recent advances in the management of hypertension in the elderly.

Authors:  F J Gennari; A S Gennari
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 3.  Matching the right drug to the right patient in essential hypertension.

Authors:  M J Brown
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

Review 4.  Hypertension and dementia.

Authors:  A S Rigaud; O Hanon; M L Seux; F Forette
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

5.  Issues of clinical trial design and data interpretations in hypertension.

Authors:  L H Kuller
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 6.  Mild cognitive impairment and dementia: the importance of modifiable risk factors.

Authors:  Thorleif Etgen; Dirk Sander; Horst Bickel; Hans Förstl
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

Review 7.  Bringing prevention in geriatrics: evidences from cardiovascular medicine supporting the new challenge.

Authors:  Angelo Scuteri; Edward G Lakatta
Journal:  Exp Gerontol       Date:  2012-03-03       Impact factor: 4.032

Review 8.  Vascular risk factors and dementia: how to move forward?

Authors:  Anand Viswanathan; Walter A Rocca; Christophe Tzourio
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

Review 9.  Hypertension in the elderly.

Authors:  M Pestana
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 10.  Prevalence and implications of uncontrolled systolic hypertension.

Authors:  William B Kannel
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.